Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

Sunesis Pharmaceuticals

DB:RYIP
Snowflake Description

Excellent balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
RYIP
DB
$48M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. The last earnings update was 29 days ago. More info.


Add to Portfolio Compare Print
  • Sunesis Pharmaceuticals has significant price volatility in the past 3 months.
RYIP Share Price and Events
7 Day Returns
9.5%
DB:RYIP
5.2%
DE Biotechs
4.3%
DE Market
1 Year Returns
-71.1%
DB:RYIP
-7.4%
DE Biotechs
-14.2%
DE Market
RYIP Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Sunesis Pharmaceuticals (RYIP) 9.5% -56.5% 12.8% -71.1% -89.7% -97.3%
DE Biotechs 5.2% -3.3% -20.3% -7.4% 19.5% -9.4%
DE Market 4.3% -9% -21.6% -14.2% -19.6% -25.6%
1 Year Return vs Industry and Market
  • RYIP underperformed the Biotechs industry which returned -7.4% over the past year.
  • RYIP underperformed the Market in Germany which returned -14.2% over the past year.
Price Volatility
RYIP
Industry
5yr Volatility vs Market
Related Companies

RYIP Value

 Is Sunesis Pharmaceuticals undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Sunesis Pharmaceuticals to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Sunesis Pharmaceuticals.

DB:RYIP Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 5 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 5.6%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:RYIP
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.05
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.048 (1 + (1- 21%) (13.12%))
1.105
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.1
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (1.105 * 5.44%)
5.62%

Discounted Cash Flow Calculation for DB:RYIP using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Sunesis Pharmaceuticals is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

Note: Free cash flow to equity valuations ignore the company's cash or debt.

DB:RYIP DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 5.62%)
2020 -31.23 Analyst x1 -29.57
2021 -36.88 Analyst x1 -33.05
2022 -31.94 Analyst x1 -27.11
2023 -8.90 Analyst x1 -7.15
2024 2.62 Analyst x1 1.99
2025 3.91 Est @ 49.2% 2.81
2026 5.25 Est @ 34.32% 3.58
2027 6.50 Est @ 23.91% 4.20
2028 7.58 Est @ 16.62% 4.63
2029 8.45 Est @ 11.52% 4.89
Present value of next 10 years cash flows $-74.00
DB:RYIP DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2029 × (1 + g) ÷ (Discount Rate – g)
= $8.45 × (1 + -0.39%) ÷ (5.62% – -0.39%)
$140.11
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $140.11 ÷ (1 + 5.62%)10
$81.09
DB:RYIP Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $-74.00 + $81.09
$7.09
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $7.09 / 111.39
$0.06
DB:RYIP Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:RYIP represents 0.87284x of NasdaqCM:SNSS
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.87284x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (USD) x Listing Adjustment Factor
= $ 0.06 x 0.87284
€0.06
Value per share (EUR) From above. €0.06
Current discount Discount to share price of €0.37
= -1 x (€0.37 - €0.06) / €0.06
-566.3%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Sunesis Pharmaceuticals is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Sunesis Pharmaceuticals's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Sunesis Pharmaceuticals's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:RYIP PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-12-31) in USD $-0.27
NasdaqCM:SNSS Share Price ** NasdaqCM (2020-04-08) in USD $0.42
Europe Biotechs Industry PE Ratio Median Figure of 24 Publicly-Listed Biotechs Companies 43.07x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 17.07x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Sunesis Pharmaceuticals.

DB:RYIP PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SNSS Share Price ÷ EPS (both in USD)

= 0.42 ÷ -0.27

-1.58x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunesis Pharmaceuticals is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Sunesis Pharmaceuticals is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Sunesis Pharmaceuticals's expected growth come at a high price?
Raw Data
DB:RYIP PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.58x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts
-7.7%per year
Europe Biotechs Industry PEG Ratio Median Figure of 19 Publicly-Listed Biotechs Companies 1.71x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.24x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Sunesis Pharmaceuticals, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Sunesis Pharmaceuticals's assets?
Raw Data
DB:RYIP PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-12-31) in USD $0.14
NasdaqCM:SNSS Share Price * NasdaqCM (2020-04-08) in USD $0.42
Germany Biotechs Industry PB Ratio Median Figure of 14 Publicly-Listed Biotechs Companies 3.37x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.47x
DB:RYIP PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SNSS Share Price ÷ Book Value per Share (both in USD)

= 0.42 ÷ 0.14

2.99x

* Primary Listing of Sunesis Pharmaceuticals.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Sunesis Pharmaceuticals is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Sunesis Pharmaceuticals's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Sunesis Pharmaceuticals has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

RYIP Future Performance

 How is Sunesis Pharmaceuticals expected to perform in the next 1 to 3 years based on estimates from 5 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-7.7%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Sunesis Pharmaceuticals expected to grow at an attractive rate?
  • Unable to compare Sunesis Pharmaceuticals's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Sunesis Pharmaceuticals's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Sunesis Pharmaceuticals's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:RYIP Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:RYIP Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts -7.7%
DB:RYIP Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts 62.3%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 38.2%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14.1%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:RYIP Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:RYIP Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2024-12-31 180 -37 3
2023-12-31 118 -41 3
2022-12-31 43 -49 3
2021-12-31 1 -47 5
2020-12-31 1 -34 5
2020-04-08
DB:RYIP Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-12-31 2 -22 -23
2019-09-30 0 -25 -24
2019-06-30 0 -25 -25
2019-03-31 0 -24 -25
2018-12-31 0 -24 -27
2018-09-30 0 -23 -27
2018-06-30 0 -28 -31
2018-03-31 0 -33 -33
2017-12-31 1 -36 -35
2017-09-30 1 -39 -37
2017-06-30 2 -37 -36
2017-03-31 3 -36 -38

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Sunesis Pharmaceuticals is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Sunesis Pharmaceuticals's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:RYIP Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below

All data from Sunesis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RYIP Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2024-12-31 -0.27 0.02 -0.55 2.00
2023-12-31 -0.26 -0.06 -0.45 2.00
2022-12-31 -0.34 -0.23 -0.45 2.00
2021-12-31 -0.34 -0.24 -0.47 5.00
2020-12-31 -0.28 -0.24 -0.34 5.00
2020-04-08
DB:RYIP Past Financials Data
Date (Data in USD Millions) EPS *
2019-12-31 -0.27
2019-09-30 -0.35
2019-06-30 -0.48
2019-03-31 -0.60
2018-12-31 -0.75
2018-09-30 -0.80
2018-06-30 -0.99
2018-03-31 -1.18
2017-12-31 -1.45
2017-09-30 -1.75
2017-06-30 -1.89
2017-03-31 -2.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Sunesis Pharmaceuticals will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Sunesis Pharmaceuticals's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Sunesis Pharmaceuticals has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

RYIP Past Performance

  How has Sunesis Pharmaceuticals performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Sunesis Pharmaceuticals's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Sunesis Pharmaceuticals does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Sunesis Pharmaceuticals's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Sunesis Pharmaceuticals's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Sunesis Pharmaceuticals's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Sunesis Pharmaceuticals Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:RYIP Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-12-31 2.07 -23.33 9.95 15.41
2019-09-30 0.00 -24.04 9.93 13.77
2019-06-30 0.00 -24.60 10.11 13.82
2019-03-31 0.00 -25.20 10.41 13.89
2018-12-31 0.24 -26.62 11.33 14.62
2018-09-30 0.24 -27.24 11.63 14.99
2018-06-30 0.24 -30.90 12.12 18.16
2018-03-31 0.24 -32.90 12.97 19.35
2017-12-31 0.67 -35.46 13.55 21.54
2017-09-30 1.35 -37.37 14.72 22.68
2017-06-30 1.96 -36.17 15.44 21.17
2017-03-31 2.57 -37.77 15.76 22.83
2016-12-31 2.54 -38.02 16.12 22.88
2016-09-30 2.53 -41.06 16.56 25.69
2016-06-30 2.60 -39.13 16.67 25.70
2016-03-31 2.85 -37.63 17.85 25.40
2015-12-31 3.06 -36.68 18.66 23.70
2015-09-30 3.29 -26.42 20.36 22.04
2015-06-30 3.46 -34.73 23.59 23.72
2015-03-31 4.59 -37.56 24.81 24.63
2014-12-31 5.73 -43.00 23.11 27.67
2014-09-30 6.83 -48.86 19.73 28.58
2014-06-30 7.96 -41.14 15.31 28.60
2014-03-31 7.96 -37.55 11.81 29.07
2013-12-31 7.96 -34.60 10.84 28.89
2013-09-30 7.96 -31.47 10.61 29.60
2013-06-30 6.23 -41.26 10.14 29.52

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Sunesis Pharmaceuticals has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Sunesis Pharmaceuticals has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Sunesis Pharmaceuticals improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Sunesis Pharmaceuticals's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Sunesis Pharmaceuticals has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

RYIP Health

 How is Sunesis Pharmaceuticals's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Sunesis Pharmaceuticals's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Sunesis Pharmaceuticals is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Sunesis Pharmaceuticals's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Sunesis Pharmaceuticals's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 6.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Sunesis Pharmaceuticals Company Filings, last reported 3 months ago.

DB:RYIP Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-12-31 27.54 5.47 29.13
2019-09-30 32.29 5.46 32.81
2019-06-30 11.74 5.46 12.18
2019-03-31 17.09 6.03 24.81
2018-12-31 3.99 7.40 13.70
2018-09-30 9.30 7.35 20.16
2018-06-30 9.98 7.30 20.43
2018-03-31 15.37 7.25 25.40
2017-12-31 21.54 7.20 31.75
2017-09-30 2.91 7.15 12.45
2017-06-30 12.47 7.09 22.68
2017-03-31 14.32 14.51 35.18
2016-12-31 21.02 14.44 42.59
2016-09-30 2.21 14.36 24.25
2016-06-30 10.06 14.28 33.12
2016-03-31 19.27 11.69 40.02
2015-12-31 27.39 7.83 46.43
2015-09-30 12.06 7.75 30.50
2015-06-30 17.18 7.67 39.56
2015-03-31 16.79 7.59 39.79
2014-12-31 13.80 9.26 42.98
2014-09-30 3.62 11.57 44.72
2014-06-30 15.84 13.81 58.54
2014-03-31 25.76 15.96 70.66
2013-12-31 -6.18 18.04 39.29
2013-09-30 -5.78 20.05 45.50
2013-06-30 -5.79 21.98 49.58
  • Sunesis Pharmaceuticals's level of debt (19.8%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (66.8% vs 19.8% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Sunesis Pharmaceuticals has sufficient cash runway for 1.3 years based on current free cash flow.
  • Sunesis Pharmaceuticals has less than a year of cash runway if free cash flow continues to reduce at historical rates of -9.6% each year.
X
Financial health checks
We assess Sunesis Pharmaceuticals's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Sunesis Pharmaceuticals has a total score of 5/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

RYIP Dividends

 What is Sunesis Pharmaceuticals's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Sunesis Pharmaceuticals dividends. Estimated to be 0% next year.
If you bought €2,000 of Sunesis Pharmaceuticals shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Sunesis Pharmaceuticals's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Sunesis Pharmaceuticals's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:RYIP Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 5 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 1.1%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.6%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.6%
Germany Top 25% Dividend Yield 75th Percentile 4.6%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:RYIP Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2024-12-31
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2020-04-08

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Sunesis Pharmaceuticals has not reported any payouts.
  • Unable to verify if Sunesis Pharmaceuticals's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Sunesis Pharmaceuticals's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Sunesis Pharmaceuticals has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Sunesis Pharmaceuticals's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Sunesis Pharmaceuticals's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Sunesis Pharmaceuticals afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Sunesis Pharmaceuticals has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

RYIP Management

 What is the CEO of Sunesis Pharmaceuticals's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Dayton Misfeldt
COMPENSATION $574,939
AGE 45
TENURE AS CEO 2.3 years
CEO Bio

Mr. Dayton Misfeldt has been an Interim CEO of Sunesis Pharmaceuticals, Inc. since January 1, 2018 and as its Director since April 2009. Mr. Misfeldt serves as Managing Director and Investment Partner at Bay City Capital LLC. Mr. Misfeldt focuses on biopharmaceutical investment opportunities and is involved in a number of investments. he joined the Bay City Capital in May 2000. He has significant capital markets expertise, financial sophistication multiple market cycles. He served as a Vice President at Roth Capital Partners, where he worked as a sell side Analyst focusing on the biopharmaceutical industry. He was also involved in raising funds for Roth's corporate finance clients and marketing Roth's capabilities to the investment community. Mr. Misfeldt served as a Project Manager at Life Sciences Economics, Inc. He served as Investment Manager of Bay City Capital LLC, Advisory Arm. He served as Equity Analyst of Roth Capital Partners, LLC, Research Division. He has been a Director of Interleukin Genetics, Inc. since May 2013. He serves as Director of TRIA Beauty, Inc. and Presidio Pharmaceuticals, Inc. He served as a Director of NextWave Pharmaceuticals, Inc. He participates as an Observer on the Boards of Directors of Metabolex and MAP Pharmaceuticals. He served as a Member of the Board of Directors at Aciex Therapeutics, Inc. He served as a Board Observer at Oculex Pharmaceuticals. Mr. Misfeldt received a B.A. degree in Economics from the University of California, San Diego.

CEO Compensation
  • Dayton's compensation has increased whilst company is loss making.
  • Dayton's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Sunesis Pharmaceuticals management team in years:

2.3
Average Tenure
48
Average Age
  • The tenure for the Sunesis Pharmaceuticals management team is about average.
Management Team

Dayton Misfeldt

TITLE
Interim CEO & Director
COMPENSATION
$575K
AGE
45
TENURE
2.3 yrs

Willie Quinn

TITLE
Senior VP of Finance & Corporate Development and CFO
COMPENSATION
$501K
AGE
48
TENURE
2.4 yrs

Judy Fox

TITLE
Chief Scientific Officer and Executive VP of Research & Development
TENURE
3.3 yrs

Steve Nava

TITLE
Vice President of Quality Assurance
TENURE
1.8 yrs

Debbie Thomas

TITLE
Senior Vice President
TENURE
4.2 yrs

Par Hyare

TITLE
Senior Vice President of Commercial
TENURE
0.8 yrs

Sean Gharpurey

TITLE
Executive Director of Project Management
TENURE
1.8 yrs

Dan Swisher

TITLE
Strategic Advisor
COMPENSATION
$565K
AGE
56
TENURE
2.3 yrs
Board of Directors Tenure

Average tenure and age of the Sunesis Pharmaceuticals board of directors in years:

9.6
Average Tenure
66
Average Age
  • The tenure for the Sunesis Pharmaceuticals board of directors is about average.
Board of Directors

Jim Young

TITLE
Non-Executive Chairman
COMPENSATION
$105K
AGE
74
TENURE
16.3 yrs

Dayton Misfeldt

TITLE
Interim CEO & Director
COMPENSATION
$575K
AGE
45
TENURE
11 yrs

Homer Pearce

TITLE
Independent Director
COMPENSATION
$100K
AGE
66
TENURE
13.8 yrs

Steve Carchedi

TITLE
Independent Director
COMPENSATION
$110K
AGE
57
TENURE
6.8 yrs

Henry Wolff

TITLE
Independent Director
COMPENSATION
$276K
AGE
70
TENURE
2.2 yrs

Dave Stump

TITLE
Independent Director
COMPENSATION
$93K
AGE
69
TENURE
13.8 yrs

Steve Ketchum

TITLE
Independent Director
COMPENSATION
$88K
AGE
54
TENURE
8.2 yrs

Nicole Onetto

TITLE
Director
AGE
66
TENURE
0.6 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
02. Apr 20 Buy William Quinn Individual 31. May 19 29. Nov 19 12,000 €0.59 €5,509
15. Jul 19 Buy Aisling Capital Management LP Company 15. Jul 19 15. Jul 19 2,500,000 €0.53 €1,332,600
X
Management checks
We assess Sunesis Pharmaceuticals's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Sunesis Pharmaceuticals has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

RYIP News

Simply Wall St News

RYIP Company Info

Description

Sunesis Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of targeted inhibitors for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalent inhibitor of Bruton’s tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies. The company is also developing SNS-510, which is in preclinical pharmacology studies for the treatment of solid tumor and hematologic malignancies; TAK-580, a pan-Raf inhibitor program that is in Phase 1 clinical trial for the treatment of pediatric low-grade glioma; and vosaroxin, a topoisomerase 2 inhibitor, which completed a Phase 3 trial in patients with relapsed or refractory acute myeloid leukemia. It has a collaboration agreement with Biogen Idec MA, Inc. to discover, develop, and commercialize small molecule BTK inhibitors; and license agreement with Takeda Pharmaceutical Company Limited to develop and commercialize preclinical inhibitors of PDK1. Sunesis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in South San Francisco, California.

Details
Name: Sunesis Pharmaceuticals, Inc.
RYIP
Exchange: DB
Founded: 1998
$43,980,853
111,393,000
Website: http://www.sunesis.com
Address: Sunesis Pharmaceuticals, Inc.
395 Oyster Point Boulevard,
Suite 400,
South San Francisco,
California, 94080,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SNSS Common Stock Nasdaq Capital Market US USD 27. Sep 2005
DB RYIP Common Stock Deutsche Boerse AG DE EUR 27. Sep 2005
BRSE RYIP Common Stock Berne Stock Exchange CH CHF 27. Sep 2005
DB A2ARHW COM PAR USD0.0001 (POST REV SPLT) Deutsche Boerse AG DE EUR 08. Apr 2020
Number of employees
Current staff
Staff numbers
24
Sunesis Pharmaceuticals employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 21:17
End of day share price update: 2020/04/08 00:00
Last estimates confirmation: 2020/03/26
Last earnings filing: 2020/03/10
Last earnings reported: 2019/12/31
Last annual earnings reported: 2019/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.